{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000875","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2022-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.592700+00:00","generated_at":"2026-06-27T09:56:06.559381+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enanta Q1 net loss $30.1M; plans to start EDP-235 Phase 1 this month","bullets":["Net loss of $30.1M ($1.48 per diluted share) vs $8.3M loss in prior-year quarter.","Royalty revenue from MAVYRET/MAVIRET was $27.6M, down from $31.7M YoY.","R&D expenses rose to $48.5M from $36.7M due to manufacturing for virology programs.","Cash and marketable securities $347.7M; expects sufficient runway for at least two years.","EDP-235 (oral COVID-19 treatment) Phase 1 dosing begins Feb 2022; RSVP topline data expected Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000875","json":"https://secwatch.observer/filing/0000950170-22-000875.json","markdown":"https://secwatch.observer/filing/0000950170-22-000875.md","text":"https://secwatch.observer/filing/0000950170-22-000875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022000875/0000950170-22-000875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022000875/enta-20220208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:56:06.559381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}